• M Patricia Rivera, Nichole T Tanner, Gerard A Silvestri, Frank C Detterbeck, Martin C Tammemägi, Robert P Young, Christopher G Slatore, Tanner J Caverly, Cynthia M Boyd, Dejana Braithwaite, Joelle T Fathi, Michael K Gould, Jonathan M Iaccarino, Stephen P Malkoski, Peter J Mazzone, Lynn T Tanoue, Nancy L Schoenborn, Javier J Zulueta, Renda Soylemez Wiener, and American Thoracic Society Assembly on Thoracic Oncology.
• Am. J. Respir. Crit. Care Med. 2018 Jul 15; 198 (2): e3e13e3-e13.

BackgroundLung cancer screening (LCS) has the potential to reduce the risk of lung cancer death in healthy individuals, but the impact of coexisting chronic illnesses on LCS outcomes has not been well defined. Consideration of the complex relationship between baseline risk of lung cancer, treatment-related harms, and risk of death from competing causes is crucial in determining the balance of benefits and harms of LCS.ObjectivesTo summarize evidence, identify knowledge and research gaps, prioritize topics, and propose methods for future research on how best to incorporate comorbidities in making decisions regarding LCS.MethodsA multidisciplinary group of international clinicians and researchers reviewed available data on the effects of comorbidities on LCS outcomes, focusing on the juxtaposition of lung cancer risk and competing risks of death, consideration of benefits and risks in patients with chronic obstructive pulmonary disease, communication of risk, and treatment of screen-detected lung cancer.ResultsThis statement identifies gaps in knowledge regarding how comorbidities and competing causes of death impact outcomes in LCS, and we have developed questions to help guide future research efforts to better inform patient selection, education, and implementation of LCS.ConclusionsThere is an urgent need for further research that can help guide clinical decision-making with patients who may not benefit from LCS owing to coexisting chronic illness. This statement establishes a research framework to address essential questions regarding how to incorporate and communicate risks of comorbidities into patient selection and decisions regarding LCS.

22 keywords...

hide…